<a href="https://laohu8.com/S/CMNDD">Clearmind Medicine Inc.</a> Expands Clinical Trial for CMND-100 in Alcohol Use Disorder with New Site at Johns Hopkins University
Clearmind Medicine Inc. has announced the expansion of its Phase I/IIa clinical trial for CMND-100, a proprietary MEAI-based oral treatment candidate for Alcohol Use Disorder (AUD). The expansion includes the activation of an additional clinical site at Johns Hopkins University School of Medicine and the enrollment of the first participant at this location. This follows the earlier enrollment of a participant at Yale School of Medicine. The trial aims to evaluate the safety, tolerability, and pharmacokinetic profile of CMND-100, along with preliminary efficacy indicators such as reductions in alcohol cravings and consumption. Results from this trial have not yet been presented. The trial is a multinational, multicenter study designed to establish the safety and optimal dosing of CMND-100, with the potential to further develop this treatment for AUD.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-063938), on July 15, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。